-
HKUST and PhIRDA Sign MoU to Establish Innovation Centers
•
The Hong Kong University of Science and Technology (HKUST) and the China Pharmaceutical Innovation and Research Development Association (PhIRDA) have signed a Memorandum of Understanding (MoU) aimed at establishing two innovation and research centers. This strategic partnership seeks to leverage HKUST’s strengths in basic research and PhIRDA’s members’ capabilities in…
-
China Releases Blue Book on Medical Insurance Fund Supervision
•
The China Health Insurance and Social Sciences Academic Press has jointly released the “Blue Book of Medical Insurance Fund Supervision: China Medical Insurance Fund Supervision and Management Development Report (2022).” This comprehensive publication provides a detailed overview of the current status, main issues, and challenges facing China’s medical insurance fund…
-
NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines
•
The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group’s (HKG: 2096) small-molecule COVID-19 therapy SIM0417 and Junshi Biosciences’ (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) in the 10th version of the COVID-19 Diagnosis and Treatment Plan. Both drugs are recommended for the treatment of symptoms…
-
ClinChoice Acquires Cromsource to Expand Global CRO Footprint
•
Sino-US Contract Research Organization (CRO) ClinChoice Medical Development has announced the acquisition of Cromsource S.r.l., a CRO operating out of Verona, Italy, and North Carolina in the US. Cromsource, founded in 1997, is a full-service, ISO-certified service provider that supports biotechs, pharmas, and medical device companies. Financial details of the…
-
Atom Bioscience’s ABP-671 Shows Positive Phase IIa Results in Gout Treatment
•
China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced positive results from a Phase IIa clinical study for its lead product, ABP-671. The randomized, double-blind, placebo-controlled trial enrolled 54 patients with gout or hyperuricemia across six cohorts, with 7 randomized to ABP-671 and 2 to placebo per…
-
Echo Biotech Secures Series A++ Funding for Exosomes Drug Development
•
Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised “tens of millions” of renminbi in a Series A++ financing round. The round was led by ZBJL Capital and Yanrui Asset Management, with participation from existing investor Baidu Venture. The proceeds will be directed towards the iteration of Echo Biotech’s…
-
AffaMed Technologies Completes First Patient Implantation for MINI WELL IOL
•
AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced the completion of the first patient implantation in the regulatory clinical trial for its MINI WELL progressive Extended Depth-of-Focus (EDOF) intraocular lens (IOL). The procedure was successfully conducted at the EYE & ENT Hospital of Fudan University…
-
CSPC Pharmaceutical Initiates Phase III Study for Mitoxantrone Liposome in Nasopharyngeal Carcinoma
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the first patient dosing in a randomized, open, positive controlled, multi-center Phase III study. The study is designed to assess the efficacy and safety of its mitoxantrone hydrochloride liposome in patients with recurrent and metastatic nasopharyngeal carcinoma (NPC) when combined with…
